Abstract
Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents and more precise delivery of radiation, the 5-year survival rates for early-stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 469-480 |
| Number of pages | 12 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2012 |
Keywords
- biological markers
- combined modality therapy
- molecular targets
- neoadjuvant
- pancreatic adenocarcinoma
- radiotherapy
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology